Feels shaky; I’ll wait for clearer signals.
Biotech trials in China lag US; regulatory hurdles and reimbursement pressure keep valuations modest despite some pipeline progress.
Basically, China biotech trials aren’t exciting the US market yet, and XBI’s rally probably won’t stick without real catalysts.
Anyone else remember the 2018 Amazon dip when folks trimmed and got punished? If we’re seeing a similar sentiment run here, does BlueTegu’s weighting actually protect you, or just amplify volatility?
E-commerce still dominates; logistics and AWS keep driving AMZN.
AMZN momentum looks intact; trend still up.
Momentum’s intact: MSFT ripping on AI headlines, breaking out on volume, while NVDA and AMZN keep leading. I’m riding the trend, adding on pullbacks, but watching for a fade if it overextends.
Market loves hype, but execution still lags.
Basically they’re saying AI is accelerating, cloud is sticky, and they expect solid growth. Feels optimistic, but not wild.
Basically, people are mixing up Snapchat’s own ad revenue with EBT, which is a separate entity. EBT’s performance isn’t directly tied to SNAP’s monetization, so the correlation feels tenuous.
Everyone’s worried EBT noise spooks SNAP, but I’m oddly calm. If engagement holds, this might just be a distraction.
Feels like the market’s overreacting to EBT noise. Snapchat’s core engagement still looks solid.
Altcoin sentiment is still fragile; without a clear catalyst or on-chain milestone, $DOGE struggles to break out. I’d rather see BTC stabilization and a few real winners before chasing again.
They say 'great news,' but it’s mostly noise.
Seen this movie: hype, then panic. I’d take profits and keep a small sleeve, not chase every dip.
Holding DASH, but this run feels frothy.
Over the last 72 hours, $DASHUSDT has rallied ~42% on BTC strength, with volume up ~68% and 24h turnover exceeding $1.2B. However, on-chain activity shows wallet counts flat while transfers are down; classic distribution phase.
Dip-buy or wait for ATH confirmation?
